Paul A. DiSilvestro discusses the 7-year follow-up results from the phase 3 SOLO1/GOG-3004 trial.
Paul A. DiSilvestro director of the Program in Women’s Oncology for Women & Infants Hospital of Rhode Island and Care New England Health System, and division director of gynecologic oncology in the Department of Obstetrics and Gynecology at The Warren Alpert Medical School of Brown University, discusses the 7-year follow-up results from the phase 3 SOLO1/GOG-3004 trial (NCT01844986). DiSilvestro presented the findings during the 2022 European Society for Medical Oncology Congress.
0:08 | The results were that the median overall survival in the maintenance olaparib arm hadn't been reached yet. Now seven years out from the last patient entered, so since the patients' diagnoses, and that's with the follow up of about 88 months in the olaparib arm and 87 months in the placebo arm. So, the median overall survival for the placebo arm was 75 months. And so, the hazard ratio of 0.55 meant that we see a 45% reduction in the risk of death for those on the maintenance olaparib arm seven years out from their diagnosis. And the other compelling point to make is 67% of women are alive in the maintenance olaparib arm seven years after diagnosis, as opposed to 46.5% in the placebo arm.